JAC Advance Access originally published online on September 8, 2005
Journal of Antimicrobial Chemotherapy 2005 56(5):847-855; doi:10.1093/jac/dki328
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation
1 Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; 2 Department of Chemistry and Technology of Drugs, University of Perugia, Via del Liceo, 06123 Perugia, Italy
Received 29 June 2005; returned 12 June 2005; revised 10 August 2005; accepted 19 August 2005
* Corresponding author. Tel: +32-16-332171; Fax: +32-16-332131; E-mail: Miguel.Stevens{at}med.kuleuven.be
Objectives: Quinolone derivatives have been shown to inhibit human immunodeficiency virus (HIV) replication at the transcriptional level. Recently, a series of new 6-aminoquinolones that are endowed with more pronounced anti-HIV activities compared with the formerly reported quinolone derivatives have been published. These potent 6-aminoquinolones were further evaluated for their broad-spectrum antiviral properties.
Methods: Latently HIV-1-infected cell lines as well as cytomegalovirus (CMV)-infected fibroblasts were used to evaluate the antiviral potency of the 6-aminoquinolone derivatives. Additionally green fluorescent protein (GFP) transactivation experiments using different promoters were conducted.
Results: The compounds completely suppressed tumour necrosis factor alpha (TNF-
)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 expression in latently HIV-1-infected OM-10.1 and U1 cell lines at non-toxic concentrations. In addition, HIV-1 mRNA production was dramatically suppressed in both cell lines in a dose-dependent manner. In the same concentration range, the compounds inhibited TNF- release from PMA-induced OM-10.1 cells but allowed TNF- production from PMA-induced U1 cells at all concentrations tested. The 6-aminoquinolone derivatives were not only inhibitory to the Tat-mediated transactivation of the HIV-1 LTR promoter, but were also found to interfere in a cell-dependent way with the transactivation process mediated from the human CMV immediate early and the human EF-1 promoter. Additionally, the 6-aminoquinolone derivatives were also found to be inhibitory to CMV replication in fibroblast cells.
Conclusions: It thus appears that the antiviral spectrum of this class of compounds is not confined to the specific inhibition of HIV but encompasses CMV as well. This broad-spectrum activity window might provide an interesting platform for future applications for the 6-aminoquinolone derivatives.
Keywords: Tat , TAR , latency
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Mercorelli, G. Muratore, E. Sinigalia, O. Tabarrini, M. A. Biasolo, V. Cecchetti, G. Palu, and A. Loregian A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus Activity Antimicrob. Agents Chemother., January 1, 2009; 53(1): 312 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stevens, M. Pollicita, C. Pannecouque, E. Verbeken, O. Tabarrini, V. Cecchetti, S. Aquaro, C. F. Perno, A. Fravolini, E. De Clercq, et al. Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1407 - 1413. [Abstract] [Full Text] [PDF]
|
|